Ultragenyx Pharmaceutical Inc. (RARE) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Ultragenyx is a biopharmaceutical company focused on rare and ultra-rare genetic diseases. The company operates as a single segment with four commercially approved products: Crysvita, Mepsevii, Dojolvi, and Evkeeza. It maintains a robust pipeline of gene therapy and small-molecule candidates, including DTX401 and UX111, which are awaiting FDA decisions.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $214 | $167 | $350 | $306 |
| Net Loss | $(92) | $(115) | $(277) | $(266) |
| Loss Per Share (Basic/Diluted) | $(0.90) | $(1.17) | $(2.73) | $(2.73) |
| Operating Cash Flow | N/A | N/A | $(294) | $(275) |
| Cash & Marketable Securities | $292 (Current) | N/A | $436 (Total) | $737 (Dec 2025) |
| Liabilities for Future Royalties | $1,202 | N/A | $1,202 | $1,216 |
Note: Cash and cash equivalents were $125 million, with $167 million in current marketable securities and $144 million in non-current marketable securities as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 28% year-over-year in Q2 2026 ($214M vs. $167M). Product sales rose 38% to $112M, driven by Crysvita (up 54%) and Evkeeza (up 50%). Royalty revenue increased 19% to $102M.
- Profitability Improvement: Net loss narrowed to $92M in Q2 2026 from $115M in Q2 2025, primarily due to revenue growth and cost management.
- Restructuring Impact: The company implemented a strategic restructuring plan in February 2026, reducing the workforce by approximately 10%. Total restructuring charges of $30M were recognized in the first six months of 2026, with all cash payments settled by June 30.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased to $436 million from $737 million at year-end 2025, reflecting operating cash burn and investment activity.
Guidance, Outlook, and Risks
- Regulatory Catalysts:
- DTX401 (GSDIa): FDA PDUFA action date set for August 23, 2026.
- UX111 (MPS IIIA): Resubmitted BLA accepted; FDA PDUFA action date set for September 19, 2026.
- GTX-102 (Angelman Syndrome): Phase 3 data expected in September/October 2026.
- Profitability Outlook: Management expects to achieve profitability in 2027, contingent on regulatory approvals and commercialization success.
- Key Risks:
- UX143 Setback: Phase 3 studies for UX143 (Osteogenesis Imperfecta) failed to meet primary endpoints in late 2025, leading to curtailment of manufacturing activities.
- Manufacturing Compliance: A Complete Response Letter (CRL) for UX111 in July 2025 cited observations from FDA inspections at the company's gene therapy facility; resolution is required for approval.
- Legal Proceedings: Ongoing patent infringement litigation regarding Dojolvi against multiple generic applicants (Navinta, Aurobindo, Somerset, Sun Pharma) and a lawsuit against manufacturer Catalent seeking over $100 million in damages.
- Capital Needs: While current resources are sufficient for 12 months, the company may require additional capital to fund operations and pipeline development.
Investor Verification Checklist
- Regulatory Decisions: Monitor FDA decisions on DTX401 (August 2026) and UX111 (September 2026) as critical value drivers.
- Manufacturing Resolution: Verify the status of FDA observations regarding the gene therapy manufacturing facility and the resubmission of the UX111 BLA.
- Legal Outcomes: Track the progress of the Dojolvi patent litigation and the Catalent manufacturing dispute, which could impact supply chain and costs.
- Cash Burn Rate: Assess the sustainability of the $294M operating cash outflow over six months against the $436M liquidity position.
- Restructuring Savings: Confirm if the anticipated cost savings from the 10% workforce reduction are materializing in subsequent quarters.